A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Shionogi
- 26 Apr 2017 Results published in the Journal of Clinical Oncology
- 02 Jun 2015 Primary endpoint has been met (Chang in frequency of spontaneous bowel movements), according to an abstract presented at at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.